New study monitors RSV vaccine safety in seniors
NCT ID NCT06546800
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 32 times
Summary
This study is monitoring 1,100 adults aged 60 and older who received the Abrysvo RSV vaccine in Japan. Researchers are tracking side effects for 28 days after vaccination to confirm the vaccine's safety in real-world conditions. No new treatment is being tested—this is a safety follow-up after the vaccine was already approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.